

1 Early immunologic response to mRNA COVID-19 vaccine in patients receiving biologics
2 and/or immunomodulators

3 Esteban Rodríguez-Martinó^{1*}, Rafael Medina-Prieto¹, Jorge Santana-Bagur²,
4 María Santé³, Petraleigh Pantoja⁴, Ana M. Espino⁵, Carlos A. Sariol^{4,5,6}, Esther A.
5 Torres^{1*}

6 ¹ MD. Division of Gastroenterology, Department of Medicine, University of Puerto Rico
7 School of Medicine, San Juan, Puerto Rico, ² Division of Infectious Diseases,
8 Department of Medicine, University of Puerto Rico School of Medicine, San Juan, ³
9 Department of Pathology, University of Puerto Rico School of Medicine, San Juan,
10 Puerto Rico, ⁴ Unit of Comparative Medicine, School of Medicine, University of Puerto
11 Rico, San Juan, Puerto Rico, ⁵ Department of Microbiology and Medical Zoology,
12 University of Puerto Rico School of Medicine, San Juan, Puerto Rico, ⁶ Department of
13 Medicine, University of Puerto Rico School of Medicine, San Juan.

14 Short Title

15 Immune response to Covid-19 vaccine in IBD

16 *Corresponding Authors

17 esteban.rodriquez3@upr.edu

18 estheratorresmd@gmail.com

19 Key Words

20 Covid, Inflammatory Bowel disease, Neutralization, Antibodies, T cells

21 Conflict of Interest

22 The authors disclose no conflicts of interest.

23

24 **Abstract**

25 Patients with immune conditions and immune-modifying therapies were excluded from
26 the Covid-19 vaccine trials. Studies have shown conflicting response to different
27 vaccines in persons receiving immune suppressors or biologics. The aim of this study is
28 to evaluate humoral and cellular response to Covid-19 vaccines in patients with
29 Inflammatory Bowel Disease (IBD) using biologic and/or immunomodulatory (IMM)
30 therapies.

31 **Methods:** Participants are adults with IBD receiving biologics or IMM planning to
32 receive a Covid 19 vaccine. Cellular immunity (CD4+ and CD8+ T cell levels) with flow
33 cytometry are measured at baseline and 2 weeks after each vaccine dose. Humoral
34 immunity (antibody titers and neutralizing capacity, VNT%) is analyzed by ELISA at
35 baseline, 2 weeks after each dose, and 6 and 12 months after vaccine. We present the
36 early results of the first 19 subjects. The study is approved by the IRB.

37 **Results:** 19 subjects (18 in biologics and 1 in IMM) who received 2 doses of the Pfizer-
38 BioNTech vaccine are included. Total IgG antibodies increased 21.13 times after the
39 first dose and 90 times after the second dose. VTN% increased 11.92 times after the
40 first dose and 53.79 times after the second dose. When compared with a healthy control
41 cohort, total IgG antibodies and VTN% were lower in the subjects after the first dose.
42 After the second dose, IgG antibodies increased but remained lower than controls, but
43 VTN% were similar to controls. CD4 and CD8 mean levels had an upward trend after
44 vaccination.

45 **Conclusions:** Neutralizing capacity response to the vaccine in subjects was similar to a
46 healthy cohort in spite of lower increases in total IgG antibodies. The CD4 and CD8
47 results observed may support the capacity to mount an effective cellular response in
48 patients on biologics. Larger studies are needed to determine vaccine efficacy in these
49 patients.

50

51

52 **Introduction**

53 Inflammatory Bowel Diseases (IBD) – Crohn’s disease (CD) and ulcerative colitis (UC) –
54 are characterized by chronic intestinal inflammation associated to dysregulation of the
55 immune system. Immune-modifying agents for treatment of IBD may result in a reduced
56 response to some vaccines [1, 2, 3]. Infliximab may be associated with suppressed
57 CD4+ and CD8+ T-cell proliferation and activation in patients with active UC [4].

58 Patients with immune conditions were excluded from COVID-19 vaccine trials.
59 Questions remain regarding the impact of medications on vaccine efficacy in this
60 population. A study showed 100% seropositivity following two-dose Pfizer-BioNTech
61 and NIH-Moderna COVID-19 vaccination in patients with IBD receiving biologics [5].
62 Infliximab has been associated with attenuated serological responses to SARS-CoV-2
63 when compared to gut-specific agent vedolizumab [6]. Data about antibody viral
64 neutralization capacity (VNT%) and cellular immunity are lacking. Our aim is to evaluate
65 humoral and cellular response to the COVID-19 vaccine in patients with IBD who are
66 using biologic and/or immunomodulatory therapy.

67 **Methods**

68 Patients with IBD between 21 and 65 years of age receiving biologics and/or
69 immunosuppressives and planning to receive a COVID-19 vaccine were invited to
70 participate. The study examines cellular immunity (CD4+ and CD8+ T-cell levels) via
71 flow cytometry at baseline and 2 weeks after each vaccine dose, and humoral immunity
72 (antibody titers and VNT%) via ELISA at baseline, 2 weeks after each dose, 6 and 12
73 months after completing vaccination. We report results of cellular and humoral immunity
74 for the first 2 months in the initial subjects and compare them with a healthy cohort.

75 **Ethical Statement**

76 The studies are approved by the Medical Sciences Campus IRB. Volunteers in the
77 control group were participating in the IRB approved clinical protocol “Molecular Basis
78 and Epidemiology of Viral infections circulating in Puerto Rico”, Pro0004333. Protocol
79 was submitted to, and ethical approval was given by, Advarra IRB on April 21, 2020.
80 That protocol also received ethical approval from the Medical Sciences Campus IRB.

81 **Results**

82 Nineteen subjects (17 with CD and 2 with UC, 10 males) who received the BNT162b2
83 mRNA Pfizer-BioNTech 2-dose vaccine are included. The mean age was 34 (range 22-
84 59). 18 participants were receiving biologic monotherapy, 1 was only on azathioprine.

85 Total IgG antibodies increased by 21.13 times (mean 0.715, SD 0.476, range 0.031-
86 1.691) after the first dose and by 90.0 times after the second dose (mean 2.261, SD
87 0.258, range 1.66-2.58). The VNT% increased by 11.92 times after the first dose and by
88 53.79 after the second dose. As shown in figure 1, the total of IgG antibodies and the %
89 of neutralizing antibodies after the first dose were significantly lower in our subjects
90 when compared with a cohort of vaccinated healthy persons. After the second dose,
91 total IgG antibodies increased but were still lower than healthy subjects, while the % of
92 neutralizing antibodies was not significantly different between the 2 groups.

93 Mean CD4 levels were 809.95 ± 234.69 , 818.63 ± 238.94 , and 967.16 ± 396.72 for visits
94 1, 2, and 3, respectively. Mean CD8 levels were 361.00 ± 141.34 , 416.26 ± 202.98 and
95 470.11 ± 284.70 for visits 1, 2, and 3, respectively. Both CD4 and CD8 mean levels
96 showed an upward trend after vaccination. (Fig 2).

97 **Discussion**

98 To our knowledge, this is the first report of both serological and cell-mediated
99 components in response to COVID-19 vaccines in patients receiving biologics for IBD.
100 Although the antibody response was low, neutralizing capacity after the second dose
101 was similar to that of a healthy cohort. The preservation and increase of the CD4+ and
102 CD8+ T-cells after each dose indicates that patients on biologics for IBD are potentially
103 capable of mounting a quantitative effective cell-mediated immune response. Whether
104 this cellular and humoral response is protective or may require additional vaccine
105 boosting remains unknown at present. Limitations of the study include the small size of
106 the population and the short follow-up period. Larger studies with longer follow up and
107 comparison between biologics with different mechanisms of action are necessary to
108 establish the efficacy of the vaccine in these patients.

109

110 **Funding**

111 This work was supported by NIGMS award U54GM133807 and by 1U01CA260541-01
112 to CAS (NCI/NIAID). The Puerto Rico Science, Technology and Research Trust also
113 supported the research reported in this work under agreement number 2020-00272 to
114 CAS and AME. Role of funder/Sponsor: The funders had no role in the design and
115 conduct of the study; collection, management, analysis, and interpretation of the data;
116 preparation, review, or approval of the manuscript; and decision to submit the
117 manuscript for publication.

118 **Author Contributions:** Drs. Rodríguez, Santana, Torres and Sariol had full access to
119 all the data in the study and take responsibility for the integrity of the data and the
120 accuracy of the data analysis. Concept and design: Rodríguez-Martinó, Santana, Sariol,
121 Torres, Santé. Acquisition, analysis and interpretation of data: all authors. Drafting of
122 the manuscript: Rodríguez-Martinó, Sariol, Torres. Critical revision of the manuscript for
123 important intellectual content: all authors. Statistical analysis: Sariol, Pantoja. Obtained
124 funding: Torres, Sariol, Espino. Administrative, technical, or material support: Sariol,
125 Santé, Pantoja. Supervision: Torres, Sariol.

126 **Additional contributions:** We acknowledge the contributions of Sofia Ojeda BS (UPR
127 School of Medicine) with subject recruitment and data collection. No financial
128 compensation was received.

129


130

131 **References**

- 132 1. Andrisani G, Frasca D, Romero M et al. Immune response to influenza A/H1N1
133 vaccine in inflammatory bowel disease patients treated with anti-TNF- α agents:
134 Effects of combined therapy with immunosuppressants. *J Crohn's Colitis* 213(4):301-
135 307.
- 136 2. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to
137 pneumococcal polysaccharide vaccination in patients with inflammatory bowel
138 disease. *Am J Gastroenterol.* 2010; 105(1): 148-154.
- 139 3. Altunöz ME, Senateş E, Yeşil A, Calhan T, Ovünç AO. Patients with inflammatory
140 bowel disease have a lower response rate to HBV vaccination compared to controls.
141 *Dig Dis Sci.* 2012; 57(4): 1039-1044.
- 142 4. Dahlen R, Strid H, Lundgren A, Isaksson S, et al. Infliximab inhibits activation and
143 effector functions of peripheral blood T cells in vitro from patients with clinically active
144 ulcerative colitis. *Scand J Immunol.* 2013;78(3):275-284.
- 145 5. Wong SE, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-
146 IBD working group. Serological response to mRNA COVID-19 vaccines in IBD
147 patients receiving biological therapies (published online April 20, 2021).
148 *Gastroenterology.* <https://doi.org/10.1053/j.gastro.2021.04.025>
- 149 6. Kennedy NA, Goodhand JR, Bewshea C, Contributors to the CLARITY IBD study, et
150 al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated
151 with infliximab. *Gut* 2021;70:865-875.

154 **Figure 1: Patients with IBD on biologics show a limited humoral immune response**
155 **to COVID-19 vaccine.** The figure shows the results for 19 subjects with IBD compared
156 with 21 healthy volunteers. Samples correspond to baseline (before vaccination), and 2-
157 weeks after the first and the second Pfizer Covid-19 vaccine doses. In average samples
158 were collected 14 days after each dose. Samples from 21 healthy volunteers were
159 available for comparison and were collected prior to vaccination (baseline) and in average
160 15 to 20 days after each dose. Of the 21 healthy volunteers, eighteen (18) received
161 Pfizer's vaccine and three (3) Moderna's formulation. **Panel A** shows the total anti-Spike
162 S1 IgG antibodies. Results show that one vaccine dose in IBD patients triggers a limited
163 antibodies response which is significantly lower compared to the healthy cohort. Five
164 patients with IBD had no detectable antibodies after the first dose. After the second dose
165 all IBD patients had detectable antibodies, however they were still significantly lower
166 compared to the healthy control group. Panel B shows the antibodies' blocking
167 capabilities measured by a surrogate viral neutralization assay (sVNT) and results are
168 provided as percentage of neutralization. After the first vaccine dose, only 38% of IBD
169 patients developed neutralizing activity (n=8) compared with 90.4% of the healthy
170 individuals (n=19). Three (3) patients with IBD developed borderline neutralizing activity
171 and 47.6% (n=10) did not develop neutralizing activity. The second vaccine shot boosted
172 the neutralizing activity and 100% of the patients had detectable neutralizing activity with
173 a magnitude similar to the healthy cohort. Interestingly, and as a potential consequence
174 of the immunosuppression therapy, the blocking baseline activity of the healthy
175 individuals is significantly higher than the IBD group. However, all those values were
176 below the detection threshold. The threshold for the total antibodies was 0.312 and for
177 the blocking activity was 30%. Statistical significance was determined by One-way
178 ANOVA multiple comparisons to test for increase or decrease among samples. Tukey's
179 multiple comparisons test was performed as post-hoc test $p < 0.05$ was considered
180 significant.
181

182



183

184

185

186 **Figure 2. Vaccine response of CD4 and CD8 T-cells in subjects with IBD.**

187 **Panel A** shows the individual absolute CD4 count at baseline and after the first and
188 second dose of the vaccine, identified with the specific biologic being used. Five
189 subjects were on infliximab, 5 on adalimumab, 5 on ustekinumab, 3 on vedolizumab and
190 1 on azathioprine. There is a mild increase in mean CD4 count after the second vaccine
191 dose. **Panel B** shows the same parameters for the individual total CD8 counts. There is
192 a small progressive increase in mean CD8 counts after each vaccine dose. These
193 findings suggest the vaccine is safe and do not support a negative effect of vaccination
194 in the cellular response of subjects with IBD receiving biologic/immunomodulatory
195 therapy. Statistical significance was determined by One-way ANOVA multiple
196 comparisons to test for increase or decrease among samples. Tukey's multiple
197 comparisons test was performed as post-hoc test $p < 0.05$ was considered significant.
198 IBD= Inflammatory Bowel Disease, USTE = ustekinumab, VEDO= vedolizumab, ADA =
199 adalimumab, IFX = infliximab, AZA = azathioprine.

200